Neutralization of ceramide as a novel approach to specifically inhibit acute GvHD
神经酰胺中和作为特异性抑制急性 GvHD 的新方法
基本信息
- 批准号:8395366
- 负责人:
- 金额:$ 28.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-01 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Graft Versus Host DiseaseAdjuvantAdjuvant TherapyAffinityAllogenicAllograftingAnimalsAntibodiesAntigensApoptosisApoptoticAttenuatedAutomobile DrivingBindingBiological AssayBone MarrowBovine Serum AlbuminCell physiologyCellsCeramidesChemotherapy-Oncologic ProcedureChronicClinicalCoculture TechniquesColony-forming unitsComplexComplicationCytotoxic T-LymphocytesDevelopmentDoseEffector CellEngraftmentEnzyme-Linked Immunosorbent AssayEventFailureFunctional disorderFundingGenerationsGeneticGenus MycobacteriumGraft-Versus-Tumor InductionHLA AntigensHalf-LifeHematopoieticHematopoietic Stem Cell TransplantationHepatocyteImmuneImmune systemImmunizationImmunocompromised HostImmunoglobulin Class SwitchingImmunoglobulin GImmunoglobulin MImmunologicsImmunosuppressionIn VitroInfectionInfection ControlInflammatoryInflammatory ResponseIntestinesInvestigationLigandsLiverMalignant NeoplasmsMammalsMediatingMembraneMinorModelingMolecularMonoclonal AntibodiesMorbidity - disease rateMusN-palmitoylsphingosineNational Institute of Allergy and Infectious DiseaseOligodeoxyribonucleotidesOrganPathologyPenetrationPharmaceutical PreparationsPhasePlasma CellsPreventionProcessRadiationReadingRefractory DiseaseRelapseResidual stateRiskScreening procedureSerumSignal TransductionSiteSkinSmall Business Innovation Research GrantSphingolipidsStem cell transplantStem cellsStressStructureSurfaceSyndromeT-Cell DepletionT-LymphocyteTestingTherapeuticTissuesToxicologyacid sphingomyelinaseattenuationbasechemokineconditioningcytokineefficacy testinggraft vs host diseasehuman diseasehumanized monoclonal antibodiesimmune functionimprovedin vivomortalitymouse modelneoplasticnovelnovel strategiespre-clinicalpreventresearch studyresponsetumorwasting
项目摘要
DESCRIPTION (provided by applicant): Acute graft-versus-host disease (GvHD) is a primary complication of allogeneic stem cell transplantation, associated with wasting, immunosuppression and specific damage to the intestines, liver and skin. GvHD results from activation of donor T cells from human leukocyte antigen (HLA)-identical or related donors against host tissues. Current therapeutic approaches to mitigate the basic underlying pathology of acute GvHD include immune-suppressive drugs or depletion of T cells from the graft, however these options render severely immunocompromised patients susceptible to infection or neoplastic relapse. As such, attenuation of GvHD- associated pathology while maintaining immune function against residual malignancy or infection is the 'holy grail' of HCST adjuvant therapies. Ceramide Therapeutics proposes the generation and development of anti- ceramide monoclonal IgG antibody as a mechanism-based approach to protect host tissue and prevent or treat acute GvHD. Evidence that ceramide regulates tissue pathophysiology during acute GvhD was obtained using mice deficient in acid sphingomyelinase (ASMase)-mediated ceramide generation as hosts for minor antigen mismatched bone marrow and T cells. Inactivation of host ASMase abrogated tissue damage during GvHD and attenuated the inflammatory response responsible for propagating CTL attack of host tissue, thereby significantly improving survival in mouse models. Investigation into the mechanism of action of hepatocyte apoptosis during GvHD revealed that CTLs induce ceramide generation on the target hepatocyte surface, driving the biophysical reorganization of the exoplasmic membrane into structures called ceramide-rich platforms (CRPs). CRPs are sites where transmembrane apoptotic signal transduction takes place, and are amenable to pharmacologic inactivation. In the current application, we propose to generate a high-affinity neutralizing anti-ceramide IgG for advancement into preclinical development.
PUBLIC HEALTH RELEVANCE: Inhibition of acute GvHD-associated pathophysiology while maintaining global immune functioning against residual malignancy and infection is the 'holy grail' of HCST adjuvant therapies. Ceramide regulates tissue pathophysiology during acute GvhD, as genetic deletion of acid sphingomyelinase (ASMase)-mediated ceramide generation abrogated tissue damage during GvHD, attenuated the inflammatory response responsible for propagating CTL attack of host tissue, and significantly improved survival in mouse models. Here we propose the generation of a high-affinity neutralizing anti-ceramide IgG to specifically inhibit GvHD pathophysiology while not impacting global T cell function, for advancement into preclinical development.
描述(由申请人提供):急性移植物抗宿主病(GvHD)是异基因干细胞移植的主要并发症,与消耗、免疫抑制和肠道、肝脏和皮肤的特异性损伤有关。GvHD由来自人类白细胞抗原(HLA)-相同或相关供体的供体T细胞针对宿主组织的活化引起。目前缓解急性GvHD的基本潜在病理学的治疗方法包括免疫抑制药物或从移植物中耗尽T细胞,然而这些选择使严重免疫功能低下的患者易于感染或肿瘤复发。因此,GvHD相关病理的减弱同时维持针对残余恶性肿瘤或感染的免疫功能是HCST辅助疗法的“圣杯”。神经酰胺治疗提出了抗神经酰胺单克隆IgG抗体的产生和开发,作为保护宿主组织和预防或治疗急性GvHD的基于机制的方法。神经酰胺在急性GvhD期间调节组织病理生理学的证据是使用缺乏酸性鞘磷脂酶(ASMase)介导的神经酰胺生成的小鼠作为次要抗原不匹配的骨髓和T细胞的宿主获得的。宿主ASMase的失活消除了GvHD期间的组织损伤,并减弱了负责传播宿主组织CTL攻击的炎症反应,从而显着提高了小鼠模型的存活率。对GvHD期间肝细胞凋亡的作用机制的研究表明,CTL诱导靶肝细胞表面上的神经酰胺产生,驱动外质膜的生物物理重组为称为富含神经酰胺的平台(CRP)的结构。CRP是跨膜凋亡信号转导发生的位点,并且适合于药理学失活。在本申请中,我们提出产生高亲和力中和抗神经酰胺IgG,以推进临床前开发。
公共卫生相关性:抑制急性GvHD相关的病理生理学,同时保持针对残留恶性肿瘤和感染的整体免疫功能是HCST辅助治疗的“圣杯”。神经酰胺在急性GvhD期间调节组织病理生理学,因为酸性鞘磷脂酶(ASMase)介导的神经酰胺生成的基因缺失消除了GvHD期间的组织损伤,减弱了负责传播宿主组织的CTL攻击的炎症反应,并且显著改善了小鼠模型中的存活率。在这里,我们提出产生高亲和力中和抗神经酰胺IgG,以特异性抑制GvHD病理生理学,同时不影响整体T细胞功能,以推进临床前开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jim Rotolo其他文献
Jim Rotolo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jim Rotolo', 18)}}的其他基金
Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide
泛冠状病毒抗病毒肽抑制 SARS-CoV-2 感染
- 批准号:
10256216 - 财政年份:2021
- 资助金额:
$ 28.48万 - 项目类别:
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer
开发细胞穿透性 β-连环蛋白拮抗剂肽作为 Wnt 驱动乳腺癌的候选治疗药物
- 批准号:
10707593 - 财政年份:2021
- 资助金额:
$ 28.48万 - 项目类别:
Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide
泛冠状病毒抗病毒肽抑制 SARS-CoV-2 感染
- 批准号:
10401492 - 财政年份:2021
- 资助金额:
$ 28.48万 - 项目类别:
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer
开发细胞穿透性 β-连环蛋白拮抗剂肽作为 Wnt 驱动乳腺癌的候选治疗药物
- 批准号:
10324076 - 财政年份:2021
- 资助金额:
$ 28.48万 - 项目类别:
Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer
C/EBP β 拮抗剂在原位乳腺癌中的疗效和 PK/PD
- 批准号:
10681209 - 财政年份:2020
- 资助金额:
$ 28.48万 - 项目类别:
Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer
C/EBP β 拮抗剂在原位乳腺癌中的疗效和 PK/PD
- 批准号:
10079655 - 财政年份:2020
- 资助金额:
$ 28.48万 - 项目类别:
Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer
C/EBP β 拮抗剂在原位乳腺癌中的疗效和 PK/PD
- 批准号:
10384382 - 财政年份:2020
- 资助金额:
$ 28.48万 - 项目类别:
Single-chain antibody countermeasures for the Radiation GI Syndrome
放射胃肠道综合症的单链抗体对策
- 批准号:
8646044 - 财政年份:2014
- 资助金额:
$ 28.48万 - 项目类别:
Single-chain antibody countermeasures for the Radiation GI Syndrome
放射胃肠道综合症的单链抗体对策
- 批准号:
8852053 - 财政年份:2014
- 资助金额:
$ 28.48万 - 项目类别:
Neutralization of ceramide as a novel approach to specifically inhibit acute GvHD
神经酰胺中和作为特异性抑制急性 GvHD 的新方法
- 批准号:
8514511 - 财政年份:2012
- 资助金额:
$ 28.48万 - 项目类别:
相似海外基金
A Novel Small Molecule Therapeutic for Acute Graft Versus Host Disease
一种治疗急性移植物抗宿主病的新型小分子疗法
- 批准号:
10759657 - 财政年份:2023
- 资助金额:
$ 28.48万 - 项目类别:
Investigation of the association between acute graft-versus-host disease and renal impairment.
急性移植物抗宿主病与肾功能损害之间关系的调查。
- 批准号:
23K19558 - 财政年份:2023
- 资助金额:
$ 28.48万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Impact of gut mycobiome on acute graft-versus-host disease
肠道真菌组对急性移植物抗宿主病的影响
- 批准号:
20K08748 - 财政年份:2020
- 资助金额:
$ 28.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Harnessing the single-cell biology and biomarker involving in the therapeutic response of patients with severe acute graft-versus-host disease undergoing mesenchymal stem cell transfusion
利用单细胞生物学和生物标志物参与接受间充质干细胞输注的严重急性移植物抗宿主病患者的治疗反应
- 批准号:
19K16605 - 财政年份:2019
- 资助金额:
$ 28.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effectiveness of dimethyl fumarate for acute graft-versus-host disease
富马酸二甲酯治疗急性移植物抗宿主病的有效性
- 批准号:
19K24001 - 财政年份:2019
- 资助金额:
$ 28.48万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Role of T cells and the Intestinal Microbiota in the Pathogenesis of Acute Graft- versus- Host Disease
T 细胞和肠道微生物群在急性移植物抗宿主病发病机制中的作用
- 批准号:
9754362 - 财政年份:2019
- 资助金额:
$ 28.48万 - 项目类别:
Frequency analysis of graft-versus-host reactive T cell clones in human acute graft-versus-host disease tissues
人急性移植物抗宿主病组织中移植物抗宿主反应性T细胞克隆的频率分析
- 批准号:
18K08321 - 财政年份:2018
- 资助金额:
$ 28.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Prevention of acute Graft-versus-Host disease after allogeneic stem cell transplantation by molecular targeting of anti-apoptotic proteins in activated donor T-cells (A08*)
通过分子靶向活化供体 T 细胞中的抗凋亡蛋白来预防同种异体干细胞移植后的急性移植物抗宿主病 (A08*)
- 批准号:
278130007 - 财政年份:2015
- 资助金额:
$ 28.48万 - 项目类别:
Collaborative Research Centres
Pathological analysis of acute graft-versus-host disease and development of molecular targeted therapy for acute GVHD
急性移植物抗宿主病的病理分析及急性GVHD分子靶向治疗的进展
- 批准号:
15K09657 - 财政年份:2015
- 资助金额:
$ 28.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Altered Exosomal miRNA expression of late onset acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
异基因造血干细胞移植中迟发型急性移植物抗宿主病外泌体 miRNA 表达的改变。
- 批准号:
26860373 - 财政年份:2014
- 资助金额:
$ 28.48万 - 项目类别:
Grant-in-Aid for Young Scientists (B)